The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Dec 2 (Reuters) - Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine could be approved for emergency use within 24 to 72 hours after the U.S. health regulator's advisory committee meeting, Chief ...

The greater part of third quarter earnings results are in the rearview mirror, though investors this week are looking to reports from The Walt Disney Company and Alibaba . So far, ...

Moderna is working on a stronger tool to fight the COVID-19 pandemic. However, officials say it will take time. The drugmaker says research is underway toward a one-dose, yearly booster to battle the ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...

Moderna's CEO says that people will likely need a fourth dose of a COVID-19 vaccine later this year. According to The Washington Post and CNBC, Moderna CEO Stéphane Bancel said at a conference hosted ...

CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...

When Moderna CEO Stéphane Bancel addressed the J.P. Morgan Healthcare Conference in January 2021 — virtually, along with the rest of the participants who tuned in at the height of the Covid-19 ...